← Eichor
Condition: Post Transplant Lymphoproliferative Disorder Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Post Transplant Lymphoproliferative Disorder

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
NA · 1 location(s) · Medical College of Wisconsin · NCT05794880Methods of T Cell Depletion Trial (MoTD)
Phase 2 · 17 location(s) · University of Birmingham · NCT04888741Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma
Phase 2 · 1 location(s) · Stanford University · NCT06461988Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05776979Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder
Phase 2 · 4 location(s) · Timothy Voorhees · NCT05786040Risk Stratification and MRD-driven Maintenance for MM After ASCT
NA · 4 location(s) · Peking University People's Hospital · NCT06697483IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
Phase 2 · 1 location(s) · Dickran Kazandjian, MD · NCT06376526Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyc
Phase 1 · 2 location(s) · University of Kansas Medical Center · NCT03533816Improved Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Protocol for the Treatment of Epstein Barr Vir
Phase 4 · 1 location(s) · Beijing Children's Hospital · NCT07029958A Study to Evaluate the Long-Term Safety of Idecabtagene Vicleucel Treatment in Adults With Newly Diagnosed Multiple Mye
Phase N/A · 5 location(s) · Bristol-Myers Squibb · NCT06698887Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus H
Phase 2/Phase 3 · 1 location(s) · Federal Research Institute of Pediatric Hematology, Oncology · NCT07366801PD-1 Inhibitors Maintenance for cHL Post-autoHCT
Phase 2 · 4 location(s) · St. Petersburg State Pavlov Medical University · NCT06812858CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT
NA · 1 location(s) · Children's Hospital of Philadelphia · NCT03810196Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma
Phase 3 · 69 location(s) · University of Heidelberg Medical Center · NCT06216158Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopo
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05091372Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Yo
Phase 2/Phase 3 · 1 location(s) · Federal Research Institute of Pediatric Hematology, Oncology · NCT06756152Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation
Phase 2 · 20 location(s) · University Hospital, Clermont-Ferrand · NCT04935684Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple My
Phase 2 · 2 location(s) · University of Illinois at Chicago · NCT05344833Mozobil for Autologous Hematopoietic Stem Cell Transplantation
Phase 2 · 1 location(s) · Thomas Jefferson University · NCT07188090Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
Phase 1/Phase 2 · 7 location(s) · Leland Metheny · NCT03104491Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in T
Phase 3 · 64 location(s) · Intergroupe Francophone du Myelome · NCT06918002A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patie
Phase 2 · 13 location(s) · Center for International Blood and Marrow Transplant Researc · NCT06859424Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137825CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transp
Phase 1 · 1 location(s) · St. Jude Children's Research Hospital · NCT07257419Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-inten
Phase 2 · 10 location(s) · University of Liege · NCT03852407Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT06575296T Cell Therapy of Opportunistic Cytomegalovirus Infection
EARLY_Phase 1 · 1 location(s) · Mari Dallas · NCT02982902Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantati
Phase 1 · 1 location(s) · Sawa Ito, MD · NCT07565220A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell
Phase 2/Phase 3 · 1 location(s) · Shanghai General Hospital, Shanghai Jiao Tong University Sch · NCT07389616Telematic Cognitive Training and Mindfulness in Pediatric Patients After CAR-T Cell Therapy, Single Hematopoietic Alloge
NA · 1 location(s) · Hospital Universitario La Paz · NCT07479927
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.